10Sep 2022
Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial

Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial

A treat-to-target study will evaluate the efficacy and safety of ultra‐rapid lispro (URLi) versus lispro in a paediatric population with type 1 diabetes (T1D) in Phase 3. In children and adolescents with T1D, URLi demonstrated reasonable glycaemic control and noninferiority to lispro in HbA1c change for mealtime and postmeal URLi. In addition, when dosed at the beginning of meals, URLi reduced 1‐hour PPG and PPG excursions versus lispro.

  • #endo-diabetology

Like

Save

Share